SCHEDULE 13G/A: Hudson Bay Capital and Sander Gerber Disclose 9.98% Stake in Psyence Biomedical Ltd.
Beneficial Ownership Report Amendment
Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, revealing a combined beneficial ownership of 9.98% in Psyence Biomedical Ltd.'s common shares.
Summary
- Hudson Bay Capital Management LP and Sander Gerber, collectively referred to as 'Reporting Persons,' have filed an Amendment No. 1 to their Schedule 13G.
- The amendment was filed to correct an inadvertent omission of a cover page for Mr. Gerber in the original Schedule 13G filed on February 10, 2025.
- The Reporting Persons beneficially own an aggregate of 380,000 common shares of Psyence Biomedical Ltd.
- This ownership represents 9.98% of the company's outstanding common shares.
- The percentage is calculated based on a total of 3,807,128 common shares outstanding, which includes 3,427,128 shares outstanding as of December 17, 2024, and the 380,000 shares purchased by the Reporting Persons on December 24, 2024.
- The shares are held in the name of Hudson Bay Master Fund Ltd., for which Hudson Bay Capital Management LP serves as the investment manager.
- Mr. Gerber is the managing member of Hudson Bay Capital GP LLC, the general partner of the Investment Manager, and disclaims beneficial ownership of these securities.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and an amendment to correct a filing error, thus it carries a neutral sentiment.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm and its principal, indicating a significant stake in Psyence Biomedical Ltd. It does not provide broader industry trends but highlights an investment firm's confidence or strategic interest in the company within its sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, which can influence market perception and trading activity.
- Company Management: Awareness of a large institutional holder's position, potentially influencing strategic decisions or engagement.
Key Dates
| Date | Description |
|---|---|
| 2024-12-17 | Date when 3,427,128 Common Shares of Psyence Biomedical Ltd. were reported outstanding. |
| 2024-12-24 | Date when Reporting Persons purchased 380,000 Common Shares in an offering. |
| 2024-12-31 | Date of event which requires filing of this statement; also the date of the Company's Prospectus filing. |
| 2025-02-10 | Date of the original Schedule 13G filing and the current Amendment No. 1 filing. |
Keywords
Psyence Biomedical Ltd., Hudson Bay Capital Management LP, Sander Gerber, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.